Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia
- The P-III (ERADICATE) study evaluating ceftobiprole (IV) vs daptomycin with/out aztreonam in 390 adult patients with SAB at 50+ study centers in Eastern & Central EU & other countries
- The trial met the pre-specified efficacy objective of overall success in the mITT population @70 days after randomization, a non-inferiority margin of 15%, and overall SR (69.8% vs 68.7%), was well tolerated. The company plans to submit ceftobiprole's NDA to the US FDA at the end of 2022
- The safety profile was consistent with prior P-III studies and the post-marketing with ceftobiprole, AEs were similar b/w treatment groups. If ceftobiprole is approved, it will receive 10yrs. of market exclusivity in the US from the date of approval
Ref: GlobalNewswire | Image: Basilea
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.